SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-García, María, Servitja Tormo, Sonia, Vilariño Quintela, Noelia, Arance Fernández, Ana, Berrocal Jaime, Alfonso, Cantos Sánchez de Ibargüen, Blanca, Del Barco Berrón, Sonia, García Campelo, Rosario, Gironés Sarrió, Regina, Manuel Sepúlveda-Sánchez, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Clinical Guides in Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986739/
https://www.ncbi.nlm.nih.gov/pubmed/35258806
http://dx.doi.org/10.1007/s12094-022-02803-0
Descripción
Sumario:Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood–brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.

Ejemplares similares